Literature DB >> 2447200

Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality.

S E Greisman1, C A Johnston.   

Abstract

Rabbit antisera to J5 (Rc) Escherichia coli and R595 (Re) Salmonella minnesota rough mutants were selected for the highest content of hemagglutinating antibodies to their respective core glycolipids. Despite titers of 1:2560 vs. J5 and 1:640 vs. R595 core glycolipids, the antisera failed to passively protect ICR or CF-1 mice against lethality induced by endotoxins from a variety of wild-type, smooth enterobacteria: E. coli O111:B4, E. coli O127:B8, Salmonella typhimurium, S. minnesota, and Citrobacter freundii. J5 antisera, however, reduced lethality from J5 core glycolipid. In contrast, O-specific rabbit antisera were consistently protective against the lethal activity of wild-type, smooth enterobacterial endotoxins, but such protection was limited to the homologous endotoxin. These findings are consistent with in vitro demonstrations of a highly restricted ability of antibodies to J5 and R595 core glycolipids to bind to endotoxins from wild-type, smooth enterobacteria.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447200     DOI: 10.1093/infdis/157.1.54

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Colony-Stimulating Factors in the Therapeutic Approach to Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

2.  Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A.

Authors:  H M Kuhn; L Brade; B J Appelmelk; S Kusumoto; E T Rietschel; H Brade
Journal:  Infect Immun       Date:  1992-06       Impact factor: 3.441

Review 3.  Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.

Authors:  I G Mitov; D G Terziiski
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

4.  alpha-GlcNAc-1-->2-alpha-glc, the Salmonella homologue of a conserved lipopolysaccharide motif in the Enterobacteriaceae, elicits broadly cross-reactive antibodies.

Authors:  N A Nnalue
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

5.  Effect of imipenem on monoclonal antibody-mediated protection against Escherichia coli O18K5.

Authors:  H Frasa; B Benaissa-Trouw; L Tavares; K van Kessel; W Hustinx; J Schellekens; K Kraaijeveld; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

6.  Cross-reactivity of monoclonal antibodies and sera directed against lipid A and lipopolysaccharides.

Authors:  H M Kuhn
Journal:  Infection       Date:  1993 May-Jun       Impact factor: 3.553

7.  A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides.

Authors:  F E Di Padova; H Brade; G R Barclay; I R Poxton; E Liehl; E Schuetze; H P Kocher; G Ramsay; M H Schreier; D B McClelland
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  All accessible epitopes in the Salmonella lipopolysaccharide core are associated with branch residues.

Authors:  N A Nnalue
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

9.  Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide.

Authors:  H S Warren; S F Amato; C Fitting; K M Black; P M Loiselle; M S Pasternack; J M Cavaillon
Journal:  J Exp Med       Date:  1993-01-01       Impact factor: 14.307

10.  Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies.

Authors:  J D Baumgartner; D Heumann; J Gerain; P Weinbreck; G E Grau; M P Glauser
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.